To provide insight into the dynamics and source of residual viremia in human
immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 …

Context.—Current guidelines recommend that individuals infected with the human
immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents …

Virologic failure, or the inability to maintain or achieve viral suppression below detectable
limits (< 50 copies/mL), occurs in some patients with human immunodeficiency virus (HIV)-1 …

Background: Current potent antiretroviral therapy (using a protease inhibitor and two
nucleoside reverse transcriptase inhibitors) produces a durable suppression of HIV …

Objective The current recommendation that patients infected with HIV-1 be treated early is
based on little evidence. We examined whether the early initiation of antiretroviral treatment …

Objectives: Triple combination treatment of HIV-1 infection using two reverse transcriptase
inhibitors and a protease inhibitor can result in significant and sustained decreases in the …

Summary Background The Delta trial showed that combination therapy (zidovudine plus
didanosine and zidovudine plus zalcitabine) substantially lengthened life and reduced …

Background In patients infected with human immunodeficiency virus type 1 (HIV-1),
combination antiretroviral therapy can result in sustained suppression of plasma levels of …

Abstract (See the Editorial Commentary by Gandhi and Deeks, on pages 733–5.)
Background. Plasma human immunodeficiency virus type 1 (HIV-1) RNA suppression< 50 …

Background Relatively little is known about the long-term durability of viral suppression in
individuals initially achieving a viral load of less than 50 copies/ml within 24 weeks of …